Wire · opportunities
Priovant nabs first FDA approval for targeted tablet in dermatomyositis
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
The FDA approved Priovant Therapeutics' Lisraya (brepocitinib), the first targeted oral TYK2/JAK1 inhibitor for dermatomyositis, with a broad label for all adults with the disease. The approval is based on Phase 3 data showing significant clinical benefit and steroid reduction, positioning the drug for strong sales growth in a rare autoimmune indication.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 27 Aug 2026 and 28 Aug 2026.
◆ ◆ The Wire takeaway
You must move quickly to offer better autoimmune therapies as steroid-heavy treatment for dermatomyositis becomes less acceptable with Lisraya's approval. This opens a sales window but expect steady uptake given the rare disease market size.
◆ Coverage
7 sources · first reported 27 Aug 2026 · latest 28 Aug 2026
◆ Related on Wire
◆ Topics